Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors-Reference-Cited by-同舟云学术

Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

Published:2021-09-30 Issue:11 Volume:27 Page:2002-2011
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Shroff Rachna T.^ORCID,Chalasani Pavani,Wei Ran,Pennington Daniel,Quirk Grace,Schoenle Marta V.,Peyton Kameron L.,Uhrlaub Jennifer L.,Ripperger Tyler J.,Jergović Mladen,Dalgai Shelby,Wolf Alexander,Whitmer Rebecca,Hammad Hytham,Carrier Amy,Scott Aaron J.,Nikolich-Žugich Janko,Worobey Michael,Sprissler Ryan,Dake Michael^ORCID,LaFleur Bonnie J.^ORCID,Bhattacharya Deepta^ORCID

Funder

U.S. Department of Health & Human Services | National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-021-01542-z.pdf

Reference60 articles.

1. Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 (2020).

2. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).

3. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2616 (2020).